Using electronic health records to predict costs and outcomes in stable coronary artery disease

Asaria, Miqdad ORCID: 0000-0002-3538-4417, Walker, Simon, Palmer, Stephen, Gale, Chris P, Shah, Anoop D, Abrams, Keith R, Crowther, Michael, Manca, Andrea, Timmis, Adam, Hemingway, Harry and Sculpher, Mark (2016) Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart, 102 (10). 755 – 762. ISSN 1355-6037

Text (Using electronic health records to predict costs and outcomes in stable coronary artery disease) - Published Version Available under License Creative Commons Attribution. Download (842kB)

• Author

Abstract

Objectives To use electronic health records (EHR) to predict lifetime costs and health outcomes of patients with stable coronary artery disease (stable-CAD) stratified by their risk of future cardiovascular events, and to evaluate the cost-effectiveness of treatments targeted at these populations. Methods The analysis was based on 94 966 patients with stable-CAD in England between 2001 and 2010, identified in four prospectively collected, linked EHR sources. Markov modelling was used to estimate lifetime costs and quality-adjusted life years (QALYs) stratified by baseline cardiovascular risk. Results For the lowest risk tenth of patients with stable-CAD, predicted discounted remaining lifetime healthcare costs and QALYs were £62 210 (95% CI £33 724 to £90 043) and 12.0 (95% CI 11.5 to 12.5) years, respectively. For the highest risk tenth of the population, the equivalent costs and QALYs were £35 549 (95% CI £31 679 to £39 615) and 2.9 (95% CI 2.6 to 3.1) years, respectively. A new treatment with a hazard reduction of 20% for myocardial infarction, stroke and cardiovascular disease death and no side-effects would be cost-effective if priced below £72 per year for the lowest risk patients and £646 per year for the highest risk patients. Conclusions Existing EHRs may be used to estimate lifetime healthcare costs and outcomes of patients with stable-CAD. The stable-CAD model developed in this study lends itself to informing decisions about commissioning, pricing and reimbursement. At current prices, to be cost-effective some established as well as future stable-CAD treatments may require stratification by patient risk.

Item Type:	Article
Official URL:	https://heart.bmj.com/
Additional Information:	© 2016 The Authors
Divisions:	LSE Health
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine H Social Sciences > HJ Public Finance
Date Deposited:	30 Jul 2019 11:51
Last Modified:	01 Nov 2024 04:27
URI:	http://eprints.lse.ac.uk/id/eprint/101257

Actions (login required)

View Item